A Novel Human-to-Mouse-to-Human Approach for the Elucidation..
First-time PCF Award Recipient
Columbia University Medical Center
Targeting Neurogenesis in Prostate Cancer The prostate..
Baylor College of Medicine, Texas
In previous studies, Dr. Joshi Alumkal has..
Joshi Alumkal, MD:
Oregon Health & Science University Knight Cancer Institute
Joe Gray, PhD and Tomasz Beer, MD
Dr. Eliezer Van Allen is an Assistant..
Dr. Attard earned an MD degree from..
Gerhardt Attard, MD, PhD:
The Institute for Cancer Research – London, UK
Dr. Arredouani earned a BS Degree in..
Mohamed S. Arredouani, PhD:
Beth Israel Deaconess Hospital – Boston, MA
Dr. Armstrong earned a BS in Biomedical..
Andrew Armstrong, MD, ScM:
Duke University – Durham, NC
Preclinical assessment of mechanisms of resistance to..
Vivek Arora, MD, PhD:
Charles Sawyers, MD
Defining strategies to overcome enzalutamide (Xtandi) resistance
The organization of DNA into super-structures is..
Irfan Asangani, PhD:
University of Michigan
Arul Chinnaiyan, MD, PhD
Characterization and therapeutic targeting of MMSET in prostate cancer
Understanding resistance to new treatments for advanced,..
Emmanuel Antonarakis, MD:
Johns Hopkins University School of Medicine
Michael Carducci, MD and Jun Luo, PhD
Understanding mechanisms of response and resistance to abiraterone (Zytiga) and enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer, by interrogation of tumor biopsies for androgen receptor splice variants.
Over 1 million prostate biopsies are performed..
Syed Adnan Ali, MD:
Mount Sinai School of Medicine
Ashutosh Tewari, MD
Intratumor Heterogeneity (ITH) in Prostate Cancer
The development of androgen axis inhibitors Zytiga®..
Rahul Aggarwal, MD:
University of California, San Francisco
Eric Small, MD
Targeting MYC-Driven Cell Cycle Progression in Neuroendocrine Prostate Cancer with Gallium Citrate PET as a Novel Biomarker of MYC Transcriptional Activity
Genomic profiling of primary and metastatic treatment-resistant..
Wassim Abida, MD, PhD :
Memorial Sloan Kettering Cancer Center
Howard Scher, MD; Charles Sawyers, MD
Investigating Treatment Selection and Resistance Using Prostate Cancer Genomics
Chief Executive Officer
Onyx Partners, Inc.